Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
M&A activity
confidence 99%
filed 2026-06-11
Item 1.01
Dana entered into definitive agreements with Eaton Corporation for a Reverse Morris Trust transaction involving a restructuring, distribution of SpinCo (Eaton's Vehicle and eMobility business), and merger of Dana into SpinCo, resulting in Dana becoming a wholly-owned subsidiary of SpinCo. This is a material change of control transaction unanimously approved by both boards, with former Dana shareholders owning approximately 49.9% of the combined entity post-closing. The transaction involves substantial asset transfers, a $1.1 billion cash payment, and $2.6 billion in bridge financing.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-11
Item 5.07
Jade Biosciences held its 2026 Annual Meeting of Stockholders with voting results on the election of two Class II Directors (Christopher Cain and Tom Frohlich), ratification of PricewaterhouseCoopers LLP as independent auditor, and approval of an amendment to the Articles of Incorporation regarding jury trial waivers.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 75%
filed 2026-06-11
Item 5.02
The filing's primary focus is the approval of cash retention payments and amended "Change in Control" benefits for named executives (Sapir, Oltmans, Musso) in connection with a restructuring plan following discontinuation of pociredir development. While the section also discloses Greg Tourangeau's departure, the bulk of the disclosure centers on compensatory arrangements—retention bonuses and severance modifications—approved by the compensation committee and board, making exec_compensation the most salient event type.
View raw filing on EDGAR →
8-K
Exec departure
confidence 72%
filed 2026-06-11
Item 5.02
Mr. Philip R. Martens retired from his positions as member and Chairman of the Board effective June 11, 2026. While the filing also discloses Mr. Venturelli's election as Chairman, the principal disclosed action centers on Martens' departure from the chairmanship—a material executive transition at the board level. The retirement of a sitting Chairman is a material event affecting corporate governance and investor assessment of the company.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-11
Item 5.07
This is a clear disclosure of shareholder vote results from Aura Biosciences' 2026 Annual Meeting of Stockholders held on June 11, 2026. The filing reports voting outcomes for two proposals: election of two Class II directors (David Johnson and Teresa Marie Bitetti) and ratification of Ernst & Young LLP as the independent auditor. The detailed vote tallies (votes for, against, withheld, and broker non-votes) are characteristic of Item 5.07 disclosures and are material to investors as they confirm governance decisions and auditor appointment.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-06-11
Item 5.02
Daniel Durn was appointed as Chief Financial Officer and Executive Vice President of Marvell Technology effective June 15, 2026, with a compensation package including $850,000 base salary, $1,000,000 sign-on bonus, and approximately 103,508 RSUs in equity grants.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-11
Item 5.07
Legence Corp. held its Annual Meeting of Stockholders on June 11, 2026, with shareholders voting on five proposals: election of Class I directors (David Coghlan and Bilal Khan), advisory approval of 2026 named executive officer compensation, frequency of future advisory compensation votes (approved for annual frequency), approval of the 2026 Employee Stock Purchase Plan, and ratification of Deloitte & Touche LLP as independent auditor. All proposals passed with substantial majorities.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-11
Item 5.07
This Item 5.07 filing discloses the results of Korro Bio's 2026 annual meeting of stockholders held on June 10, 2026, including: (1) election of two Class I directors (Nessan Bermingham and Rachel Meyers) for three-year terms; (2) non-binding advisory approval of named executive officer compensation; and (3) ratification of Ernst & Young LLP as independent auditor. These are routine but material shareholder vote outcomes that affect board composition and governance.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-06-11
Item 8.01
Allbirds increased the maximum aggregate offering price under its at-the-market (ATM) offering program by $48.1 million of Class A common stock on June 11, 2026. This is a registered equity issuance program that will dilute existing shareholders and represents a material capital-raising activity. The filing explicitly references the prospectus supplement and registration statement, confirming this is a formal dilutive equity offering.
View raw filing on EDGAR →
8-K
M&A activity
confidence 75%
filed 2026-06-11
Item 1.01
IQVIA completed issuance of €950 million in senior notes on June 11, 2026, pursuant to a definitive indenture agreement. The proceeds are being used to refinance existing indebtedness, representing a material capital structure and debt financing event.
View raw filing on EDGAR →
8-K
M&A activity
confidence 75%
filed 2026-06-11
Item 8.01
Qwest settled exchange offers on June 11, 2026, issuing approximately $1.38 billion in aggregate principal amount of new notes (6.500% Notes due 2051 and 6.750% Notes due 2052) in exchange for outstanding old notes, with consent solicitations to amend existing indentures. This represents a material debt restructuring transaction that affects the company's capital structure and financial obligations, warranting classification as a material activity involving a significant refinancing/exchange of securities.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-11
Item 5.07
This is a clear Item 5.07 disclosure of shareholder voting results from Nkarta's June 10, 2026 annual meeting. The filing reports the outcomes of four distinct votes: election of two Class III directors (Ali Behbahani and Zachary Scheiner), ratification of Ernst & Young LLP as auditor, advisory approval of named executive officer compensation, and an advisory vote on the frequency of future compensation votes. These are routine but material governance matters that inform investors of shareholder decisions.
View raw filing on EDGAR →
8-K
Auditor Change
confidence 98%
filed 2026-06-11
Item 4.01
The filing discloses the dismissal of Baker Tilly US, LLP as the Company's independent registered public accounting firm and the appointment of PricewaterhouseCoopers LLP as the successor auditor, both approved by the Audit Committee on June 10, 2026. This is a classic auditor change under Item 4.01, and is material because it affects the registrant's financial reporting oversight and audit quality assurance.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-06-11
Item 5.07
This Item 5.07 disclosure presents the final voting results from Quince Therapeutics' Annual Meeting of Stockholders held on June 11, 2026, covering five proposals: election of a Class I director (June Bray), approval of a reverse stock split amendment (1-for-10 to 1-for-100 ratio), ratification of BDO USA as independent auditor, advisory approval of named executive officer compensation, and adjournment authority. All proposals were approved by stockholders. The reverse stock split authorization is particularly material as it represents a significant corporate action that could affect share structure and investor holdings.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-11
Item 8.01
Intuit issued $1.75 billion in aggregate principal amount of senior notes ($750M due 2031 at 4.950% and $1B due 2036 at 5.500%), with net proceeds of approximately $1.74 billion intended for general corporate purposes including potential refinancing of existing debt. While this is a material financing event affecting the registrant's capital structure and liquidity, it does not fit cleanly into the more specific event categories (not a dilutive equity issuance, not M&A activity, not a covenant breach or going-concern disclosure). The disclosure is routine debt issuance disclosure under Item 8.01, making "other_material" the most appropriate classification.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-06-11
Item 5.07
This Item 5.07 discloses the results of the Company's June 9, 2026 annual meeting of shareholders, including voting outcomes on three matters: (1) election of six trustees, where all candidates failed to meet the two-thirds vote requirement but will continue in office under Maryland law; (2) ratification of Deloitte & Touche LLP as independent auditor, which passed; and (3) an advisory say-on-pay resolution that was rejected by shareholders. The disclosure of shareholder vote results, particularly the failure of the say-on-pay proposal and the trustee election shortfall, is material to investors assessing governance and compensation practices.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-11
Item 5.07
This is a clear disclosure of shareholder vote results from Fractyl Health's 2026 Annual Meeting of Stockholders held on June 10, 2026. The filing reports voting outcomes for two matters: (1) election of three Class II directors (Marc Elia, Clive Meanwell, and Ian Sheffield), and (2) ratification of Ernst & Young LLP as independent auditors. All matters were approved. This is a routine but material disclosure required under Item 5.07 of Form 8-K.
View raw filing on EDGAR →
8-K
Other material
confidence 70%
filed 2026-06-11
Item 8.01
Seagate announced a redemption of $1 billion in 3.50% Exchangeable Senior Notes due 2028, with a redemption date of September 8, 2026. This debt management action affects the company's capital structure and involves convertible debt that may result in shareholder dilution through the exchange mechanism.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-06-11
Item 2.02
The filing discloses J. W. Mays, Inc.'s financial results for the three and nine months ended April 30, 2026, including revenues and net loss figures with year-over-year comparisons. A press release reporting quarterly financial results is the classic earnings_release event, and Item 2.02 is the standard disclosure location for such announcements.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-11
Item 7.01
The registrant announced a second quarter cash dividend of $0.45 per share via press release on June 11, 2026. While dividend declarations are routine for REITs like Chimera Investment Corp, they are material to investors as they directly affect shareholder returns and are a key metric for evaluating the company's financial health and distribution capacity. This does not fit the earnings_release category (which typically discloses quarterly/annual financial results) but represents a material capital allocation decision.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-11
Item 5.07
This Item 5.07 disclosure reports the final voting results from Chimera Investment Corp's June 10, 2026 annual meeting of stockholders. The filing presents detailed vote tallies for three proposals: election of three Class I Directors (Kevin G. Chavers, Gerard Creagh, and Susan Mills), a non-binding advisory vote on executive compensation, and ratification of Ernst & Young LLP as independent auditor. All three proposals passed with substantial majorities. This is a textbook shareholder_vote_results event.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-06-11
Item 2.02
The filing explicitly discloses an earnings release announcing "results of operations for the fiscal quarter ended April 30, 2026," distributed via wire service and posted to the company's investor relations website. The earnings release is furnished as Exhibit 99.1 under Item 2.02 of Form 8-K, which is the standard Item for quarterly financial results disclosure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-11
Item 5.02
The Board approved the appointment of Yiftach Kleinman as Chief Executive Officer, effective no later than September 8, 2026, with a base salary of NIS 80,000/month, bonus structure, and an equity grant of 53,600 options. Mr. Balucka was relieved from the CEO role as part of this leadership transition.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-06-11
Item 5.07
This Item 5.07 discloses the results of Triller Group Inc.'s 2025 annual meeting of shareholders held on June 10, 2026, including voting outcomes on six proposals: election of four directors, ratification of auditors, approval of a reverse stock split (up to 1-for-10), approval of a name change to "Eight Holdings Inc.," approval of a 2026 Equity Incentive Plan with 39.6 million shares reserved, and approval of a PIPE financing of up to $300 million. The shareholder votes on the reverse split, name change, equity plan, and dilutive PIPE financing are material to investors' assessment of the company's capital structure and strategic direction.
View raw filing on EDGAR →
8-K
M&A activity
confidence 96%
filed 2026-06-11
Item 2.01
Adial Pharmaceuticals completed the acquisition of Azora Therapeutics on June 11, 2026 pursuant to a two-step merger agreement, with Azora becoming a wholly owned subsidiary. Azora stockholders received 437,474 shares of Common Stock and 12,930.617 shares of Series A Preferred Stock, resulting in Azora equityholders holding approximately 86.9% of outstanding shares on a fully diluted basis, constituting a change of control requiring Nasdaq approval.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-11
Item 3.02
In connection with the Azora acquisition, Adial issued 437,474 shares of Common Stock, 12,930,617 shares of Series A Preferred Stock convertible into common shares, and warrants exercisable for up to 35,342,844 shares of Common Stock, all issued pursuant to the Merger Agreement and financing arrangements in reliance on Section 4(a)(2) exemption.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-06-11
Item 5.02
Matt Davidson, Ph.D. was appointed as Chief Development Officer and Class I Director, and Wendy B. Young, Ph.D. was appointed as Class III Director, both effective immediately upon closing of the Azora merger on June 11, 2026.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-11
Item 2.03
Adial Pharmaceuticals guaranteed the Azora Notes upon closing of the merger, creating a direct financial obligation that arises from the material acquisition transaction.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-11
Item 5.02
The filing discloses the appointment of Roy Cohen as Chief Financial Officer, effective June 1, 2026. The principal action is a person taking a role—a named executive officer position. While compensation terms are disclosed (NIS 55,000–65,000 per month), the core event is the appointment itself, not a compensation arrangement. CFO appointments are material to investors as they affect financial reporting oversight and corporate governance.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-11
Item 8.01
The Board postponed the 2026 Annual Meeting scheduled for June 18, 2026, citing a need for "additional time to evaluate certain matters relating to the Annual Meeting and the business to be presented to stockholders." While the disclosure does not specify the underlying issues, the vague language about evaluating "certain matters" relating to both the meeting and business operations, combined with the decision to postpone without a rescheduled date, suggests potential material concerns that do not fit neatly into standard event categories. This is material to investors as it signals unspecified governance or operational issues requiring investigation.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-06-11
Item 5.02
The filing discloses the removal of Christodoulos Tzoutzakis as Chief Operating Officer and Chief Technology Officer, effective June 11, 2026. This is a departure of a named executive officer from material positions. Although the Board explicitly states the removal was "without cause" and not due to disagreement or operational issues, the principal disclosed action is a person leaving executive roles, which is the defining characteristic of exec_departure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-11
The filing discloses the appointment of Mr. Theocharis Vasilakis as Chief Technology Officer of Elvictor Group, Inc., effective June 11, 2026, with direct reporting to the CEO and responsibility for technology strategy, digital transformation, AI/ML infrastructure, and software engineering operations. This is a material executive appointment under Item 5.02, as the CTO role is a senior officer position with significant operational responsibilities.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-11
Item 8.01
The Company discloses a material restructuring of a previously announced acquisition: the 2022 Agreement for an 80.1% equity stake in SMS is being superseded by a proposed direct asset acquisition of the Cross-Caribou mining asset. While no definitive agreement has been executed for the 2026 Asset Acquisition, the disclosure of this strategic pivot—from equity acquisition to asset acquisition—would affect a reasonable investor's assessment of the Company's M&A strategy and asset base. The event does not fit cleanly into ma_activity (no definitive agreement yet) but represents a material change in transaction structure that warrants disclosure.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-06-11
Item 8.01
The filing discloses completion of a previously announced business combination between Mountain Lake Acquisition Corp. (MLAC) and Avalanche Treasury Corporation (AVAT), with the combined company commencing trading on Nasdaq under ticker "AVAT" on June 11, 2026. The consummation of a material acquisition/merger is a core M&A activity event that materially affects the registrant's structure and investor interests.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-11
Item 1.01
Melar Acquisition Corp. entered into a material definitive agreement with its sponsor for a promissory note of up to $1.5 million to fund working capital advances, bearing 17.5% interest with a conversion-to-warrant feature.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 75%
filed 2026-06-11
Item 3.02
The Company issued 5,621,621 Class A Ordinary Shares to the Sponsor through conversion of Class B shares, relying on Section 3(a)(9) exemption, materially altering the share structure and voting control.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-06-11
Item 5.07
This Item 5.07 disclosure presents the results of an Annual Meeting of Shareholders held on June 11, 2026, where shareholders voted on two matters: (1) election of five board members with detailed vote tallies for each director, and (2) ratification of BDO USA, P.C. as the independent auditor. The filing directly matches the shareholder_vote_results event type, which covers results of votes at annual or special meetings of security holders.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-06-11
Item 2.02
The filing discloses results of operations for the fiscal quarter ended April 30, 2026, with a press release furnished as Exhibit 99.1 under Item 2.02. This is a standard quarterly earnings release disclosure, which is material to investors assessing the registrant's financial performance and condition.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-11
Item 8.01
The disclosure describes the consummation of Tribeca Strategic Acquisition Corp.'s IPO on June 1, 2026, generating $140 million in gross proceeds from 14 million units at $10.00 per unit, plus concurrent private placement sales of $4.7 million. While this is a material capital-raising event affecting the registrant's financial position, it does not fit neatly into the standard 8-K taxonomy—it is neither a traditional earnings release, M&A activity, nor a financial restatement. As a SPAC IPO completion disclosure, it is material to investors but best classified as other_material.
View raw filing on EDGAR →
8-K
M&A activity
confidence 85%
filed 2026-06-11
Item 1.01
RMG ML Sports Holdings consummated its IPO on June 11, 2026, raising $200 million through the issuance of 20 million units at $10 per unit, with entry into multiple material definitive agreements (underwriting agreement, rights agreement, investment management trust agreement, registration rights agreement, and private placement agreement) that fundamentally change the company's capital structure and public status.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-11
Item 3.02
The company completed an unregistered private placement of 210,000 Units to the Sponsor at $10.00 per unit, generating $2.1 million in gross proceeds, relying on the Section 4(a)(2) exemption from registration in connection with the IPO.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-11
Item 5.02
Keith Wyness and Robert Warfield were appointed to the board of directors effective June 9, 2026, and Grinberg, Wyness, and Warfield were appointed to three board committees (Audit, Compensation, and Corporate Governance and Nominating) with specified chair roles in connection with the company's IPO.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-11
Item 8.01
This disclosure announces an update to the terms of a shareholder extension vote scheduled for June 16, 2026, specifically increasing the Sponsor's monthly contribution cap to the Trust Account from $40,000 to $80,000. While the filing relates to a shareholder meeting and proxy solicitation, the core event is a material amendment to the economic terms of the extension arrangement that affects shareholder value and redemption economics. This does not fit cleanly into shareholder_vote_results (which covers vote outcomes, not pre-vote amendments) or other standard categories, making other_material the most appropriate classification.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-06-11
Item 3.02
VEEA Inc. issued approximately 3.66 million shares of common stock through two mechanisms: automatic conversion of $750,000 in convertible notes into 1,891,388 shares and issuance of 1,765,296 additional shares to settle prior conversion delays. These unregistered securities were issued to existing investors in transactions exempt under Section 4(a)(2) of the Securities Act, representing significant dilution to existing shareholders.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-11
Item 8.01
The filing discloses completion of an IPO generating $172.5 million in gross proceeds and a concurrent private placement of warrants generating $3.6 million, with approximately $173.4 million placed in trust. While this is a material capital-raising event, it does not fit cleanly into the earnings_release or dilutive_issuance categories—it is a post-IPO confirmation of consummation rather than a prospective offering disclosure or earnings announcement. The event is material to investors but is best classified as other_material given the specific post-closing nature of the disclosure.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-06-11
Item 5.01
Jakhongir Abidovich Artikkhodjaev acquired 3,000,000 shares (74.2% of outstanding stock) from two sellers for $750,000, resulting in a change of control of StageWise Strategies Corp. effective June 5, 2026.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-06-11
Item 5.02
Following the change of control, new executive leadership was appointed effective June 5, 2026: Elmurod Sopiev as CEO, Temur Zokirov as Chairman/CFO/Secretary, and two independent directors (Bahtiyor Kadirov and Elina Davidyan). Three prior executives (Viktor Balan, Alarcon Martinez Marcelo Ramon, and Anna Toczko) resigned in connection with the transaction.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-11
Item 8.01
The filing discloses completion of an initial public offering (IPO) on June 5, 2026, generating $201.25 million in gross proceeds from the sale of 20.125 million units, plus a concurrent private placement of 540,000 units generating $5.4 million. While this is a material capital-raising event, it does not fit neatly into the standard 8-K taxonomy—it is neither a traditional earnings release, M&A activity, nor a dilutive issuance in the sense of a secondary offering by an already-public company. The disclosure is primarily confirmatory of an already-announced IPO and trust account establishment, making "other_material" the most appropriate classification.
View raw filing on EDGAR →
8-K
Restatement
confidence 99%
filed 2026-06-11
Item 4.02
The Audit Committee concluded on June 9, 2026 that the Company's previously issued audited financial statements for fiscal years ended September 30, 2025 and 2024, and unaudited interim financial statements for multiple periods, "should not be relied upon and require restatement" due to errors in warrant accounting, SEPA accounting, and restricted stock award accounting. The Company is filing amended 10-K/A and 10-Q/A forms with restated financial statements. This is a classic Item 4.02 restatement disclosure with unmistakable language indicating non-reliance on prior financial statements.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-06-11
Item 1.01
Hyperscale Data entered into a Pre-Paid Advance Agreement with Yorkville under which the Company will receive $15 million in proceeds in exchange for the right to issue shares of Class A common stock at prices as low as 90% of VWAP (with a $0.10 floor). The agreement contemplates issuance of PPA Shares at Yorkville's discretion with potential dilution capped by an Exchange Cap and registration availability.
View raw filing on EDGAR →